Riyaz Shah, FRCP, PhD, Maidstone and Tunbridge Wells NHS Trust, Kent, UK, highlights data coming from the RAMES study (NCT03560973) which evaluated the addition of ramucirumab, a VEGFR2 inhibitor, to gemcitabine in patients with relapsed, advanced mesothelioma. Dr Shah also highlights data coming from other recent studies in mesothelioma. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).